Pioneering INNOVATIVE Solutions for Neurodegenerative Diseases

SkyBio is a biopharmaceutical company that aims to develop new drug entities for neurodegenerative diseases, including Parkinson’s disease (PD), PD with Dementia (PDD), Dementia with Lewy Bodies (DLB) and other alpha-synucleinopathies.

About us


Emphasizing the need for novel medication to treat movement and memory disorders through robust disease-modifying therapies with minimal side effects and negligible burden on patients and caregivers.


Bringing viable diagnostics that help confirm disease and reliably measure drug effects on misfolded proteins, such as alpha-synuclein and tau, to the forefront of modern medicine.


Advances a unique biotechnology platform that aims to use nanoparticles as novel and safe methods for drug delivery into the CNS and other tissues.


SkyBio is dedicated to detecting and developing projects that have an impact on neurodegenerative diseases, which we believe is primarily cause by inflammation. We strive to generate shortcuts to early diagnosis and novel therapeutic strategies for neurodegenerative diseases. Our products are proprietary with protection though extended patents.


SKYBO1 is a novel first-in-class and best-in-class new chemical entity, small molecule oral drug that penetrates the brain and initiates an increase in brain dopamine, reduction of brain alpha-synuclein and activation of D1 dopamine receptors.



SKB02 is a nanoparticle engineered to facilitate drug delivery into the brain. This new platform emphasizes the need to deliver drugs across the BBB and provide therapies for neurodegenerative and other diseases.



SKB03 is a diagnostic tool based on immunodetection assays to identify misfolding of proteins in body fluids in order to increase precision and confirmation of pathology that underlie protein misfolding, including alpha-synuclein and Tay.



We are currently focusing on the reorientation of drugs capable of inhibiting aggregation and neuroinflammation, which at the same time have good antioxidant activity to prevent mitochondrial damage. Other vital and synergistic projects include finding more reliable ways to detect and diagnose neurodegenerative diseases at a much earlier stage.

novel treatments

SkyBio is designing and testing novel molecules. We have defined the structural determinants for antiaggregant properties and are working in collaboration with experts in chemical synthesis in order to obtain different families of compounds that inhibit the reversal of this toxic aggregation.

novel treatments

innovative delivery methods

The BBB plays a key role in the generation and maintenance of chronic inflammation. SkyBio is finding new, innovative ways to deliver molecules into the brain. Our research is helping us develop viable diagnostics for confirming diseases and reliably measuring drug effects on misfolded proteins across the blood-brain barrier.

innovative delivery methods

diagnostic tool

There is no biochemical analysis of blood or cerebrospinal fluid, or a diagnostic test for PD, and clinical manifestations in early stages are difficult to detect. SkyBio early detection diagnostic tool is pioneering a new approach that allows for the quantification of aggregated protein species in biological fluids, offering immense potential for the early detection of these debilitating diseases.

diagnostic tool


SkyBio has a robust development pipeline of technologies that are being developed with prestigious entities under public-private Research and Development agreements. Our technologies strive to offer patients suffering from neurodegenerative diseases with a reliable and safe treatment with minimal side effects. All of our technologies have a high impact in the health area, with the aim of catalyzing their transfer to the pharmaceutical industry.

phase 1
phase 2
phase 3


SkyBio is the brainchild of Claude Burgio. Claude wanted to create an alternative treatment for Parksinson’s Disease. Working alongside leading scientists from the Tucumán province in northwest Argentina, the National Scientific and Technical Research Council of Argentina (CONICET), and Dr Charbel Moussa, MBBS, PhD, SkyBio was born...

claude burgio

Founder Chairman & CEO

Claude brings experience from previous roles at SkyOnline, Lockheed Martin, Intelsat and Aerospatiale. Claude Burgio holds a 1969 - 1970 Post Graduate in Supersonic flows at von Karman Institute for Fluid Dynamics, Brussels.


Contact Us

If you have an inquiry or would like to speak to the team behind SkyBio, please submit our contact form or contact us directly via email on

Thank you for submitting our contact form. Someone from the SkyBio team will be in touch with you soon.